BSTC BioSpecifics Technologies Corp

+1.27  (+2%)
Previous Close 69.7
Open 69.85
Price To Book 5.63
Market Cap 516529525
Shares 7,278,139
Volume 52,927
Short Ratio
Av. Daily Volume 44,794

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Endo is currently performing a commercial assessment.
Plantar fibromatosis
Phase 2 topline data released June 2016 - endpoints met
Human lipomas
BLA filing 2H 2019.
XIAFLEX (collagenase clostridium histolyticum) - RELEASE
Edematous fibrosclerotic panniculopathy (“cellulite”)
Phase 2b trial did not meet endpoint. Endo is currently performing a commercial assessment.
Adhesive Capsulitis (“Frozen Shoulder syndrome”)
Phase 1 data released October 31, 2018 - primary endpoint of safety and tolerability met.
Uterine fibroids

Latest News

  1. Is BioSpecifics Technologies Corp. (NASDAQ:BSTC) A Volatile Stock?
  2. Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results
  3. BioSpecifics (BSTC) Upgraded to Buy: Here's What You Should Know
  4. Is BioSpecifics Technologies (BSTC) Stock Outpacing Its Medical Peers This Year?
  5. Is BioSpecifics Technologies Corp.’s (NASDAQ:BSTC) Balance Sheet Strong Enough To Weather A Storm?
  6. Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza
  7. INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data
  8. Weakness Seen in Champions Oncology (CSBR) Estimates: Should You Stay Away?
  9. Karyopharm Files MAA for Myeloma Candidate Selinexor in EU
  10. Neurocrine Gives Ingrezza Sales View, Updates on Pipeline
  11. Spectrum Pharma Fully Enrolls 1St Cohort in Poziotinib Study
  12. Flexion Starts Phase III Enrollment on Zilretta for Hip OA
  13. Portola Up as Large-Scale Andexxa Production Gets FDA Nod
  14. Spectrum Pharma Files BLA for Neutropenia Candidate Rolontis
  15. Is BioSpecifics Technologies (BSTC) Outperforming Other Medical Stocks This Year?
  16. Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds
  17. Here’s What BioSpecifics Technologies Corp.’s (NASDAQ:BSTC) P/E Is Telling Us
  18. Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya
  19. Jazz (JAZZ) Increases Share Buyback Authorization by $400M
  20. Novan Announces Top-Line Data From Mid-Stage Molluscum Study